Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

Resolutions from the Annual General Meeting of Novo Nordisk A/S

View original at finance.yahoo.com
Resolutions from the Annual General Meeting of Novo Nordisk A/S Novo Nordisk A/S Bagsværd, Denmark, 26 March 2026 – Today, Novo Nordisk A/S held its Annual General Meeting…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Novo Nordisk is reshaping its traditional approach to patient care and market access, needing to meet patients where they are

    60% confidence

  • 2025 was a year of profound transformation for Novo Nordisk

    60% confidence

  • The year ahead will test Novo Nordisk's determination and capabilities, but the company faces it with confidence

    60% confidence

  • Novo Nordisk's renewed focus, strengthened competencies and commitment to people with serious chronic diseases position them well for challenges and opportunities ahead

    60% confidence

Data points we hold from this source

Novo Nordisk A/S · final dividend per share7.95 DKK
Novo Nordisk A/S · dividend per share11.70 DKK
Novo Nordisk A/S · share par value0.10 DKK
Novo Nordisk A/S · authorized share repurchase limit10 percent
Novo Nordisk A/S · authorized share capital increase44650000 DKK
Novo Nordisk A/S · interim dividend per share3.75 DKK
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Resolutions from the Annual General Meeting of Novo Nordisk A/S — Source | Via News | ViaNews EU